Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients (BIOIMMUN)
Multicenter, Randomized Study to Evaluate the Effectiveness of the Individualization of the Immunological Risk Based on Biomarkers (Disparity of HLA and IFN-γ ELISPOT) to Optimize Immunosuppressor Treatment in Living-donor Renal Recipients
Sponsor: Department of Health, Generalitat de Catalunya
A PHASE4 clinical study on Kidney Transplant Failure and Rejection, this trial is ongoing. The trial is conducted by Department of Health, Generalitat de Catalunya and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Feb 2021 — Feb 2023 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Unknown Status PHASE4
▶ Show 3 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2020 [monthly]
Recruiting PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health, Generalitat de Catalunya
- ORIOL BESTARD
For direct contact, visit the study record on ClinicalTrials.gov .